Skip to main content
Fig. 6 | Cancer & Metabolism

Fig. 6

From: CYP19A1 regulates chemoresistance in colorectal cancer through modulation of estrogen biosynthesis and mitochondrial function

Fig. 6

Estrogen supplementation reverses the chemosensitizing effects of CYP19A1 inhibitors but not mitochondrial complex I inhibitors in CRC cells. (A-F) Cell viability of 5-fluorouracil (5FU-R; A, D), irinotecan (IRI-R; B, E), and oxaliplatin (OXA-R; C, F) resistant SW480 cells treated with DMSO (vehicle control), anastrozole (Anas, CYP19A1 inhibitor), anastrozole plus estradiol (Anas + E2), IACS-010759 (IACS, mitochondrial complex I inhibitor), or IACS-010759 plus estradiol (IACS + E2) was assessed using the sulforhodamine B (SRB) assay. Dose-response curves were generated using the Four Parameter Logistic (4PL) model. (G-I) Dose-response curves of parental SW480 cells treated with varying concentrations of 5FU (G), IRI (H), and OXA (I) in combination with DMSO, Anas, or IACS. Data points represent mean ± SD. (A-I) n = 3

Back to article page

Cancer & Metabolism

ISSN: 2049-3002